Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIc Study

Ikuro Matsuba, Tasuku Sawa, Takehiro Kawata, Akira Kanamori, Dingfeng Jiang, Hideo Machimura, Hiroshi Takeda, Jeong Hee Han, Ke Wang, Keiji Tanaka, Li Shen, Miho Ajima, Mizuki Kaneshiro, Sang-Wook Kim, Shinichi Umezawa, Taro Asakura, Shuichi Suzuki, Seoyoung C Kim, Ikuro Matsuba, Tasuku Sawa, Takehiro Kawata, Akira Kanamori, Dingfeng Jiang, Hideo Machimura, Hiroshi Takeda, Jeong Hee Han, Ke Wang, Keiji Tanaka, Li Shen, Miho Ajima, Mizuki Kaneshiro, Sang-Wook Kim, Shinichi Umezawa, Taro Asakura, Shuichi Suzuki, Seoyoung C Kim

Abstract

Introduction: Guidelines recommend insulin progression for patients with type 2 diabetes (T2D) with inadequate glycemic control. The Multinational Observational Study Assessing Insulin use (MOSAIc [ClinicalTrials.gov identifier, NCT01400971]) study is a 2-year observational study, investigating factors that influence insulin progression in T2D patients. In this first of two reports, we describe baseline clinical and psychosocial characteristics of Chinese, Japanese, and South Korean patients who participated in MOSAIc. Insulin treatment, factors affecting progression, and outcomes will be reported separately.

Methods: Patients with T2D using insulin for ≥3 months were eligible. Baseline demographic, clinical, and psychosocial data were collected from patients. Quality of life instruments, including the Diabetes Distress Scale (DDS), were used to assess patient's concerns about disease management, support, and emotional burden. The association between the DDS and the selected covariates was also assessed.

Results: A total of 373 patients in China, 157 in Japan, and 141 in South Korea were enrolled from July 2011 to July 2013. Mean ± standard deviation duration (years) of T2D differed across countries (China 11.4 ± 7.5; Japan 13.8 ± 8.7; South Korea 15.7 ± 8.8; P < 0.0001). Japanese patients used more noninsulin anti-hyperglycemic agents than did Chinese or South Korean patients (P < 0.0001). Exclusive use of basal insulin was most common in Japan and South Korea compared with China, whereas approximately 66.8% of Chinese patients used mixed insulin. Covariates associated with the DDS were younger age [P = 0.044 (Japan)], higher incidence of monthly hypoglycemia [P = 0.036 [China]; P = 0.021 (South Korea)], and male gender [P = 0.037 (South Korea)].

Conclusions: There were significant differences amongst East Asian patients with T2D treated with insulin, including in quality of life scores. Results from the MOSAIc longitudinal analyses will further investigate trends of insulin intensification and barriers to insulin progression.

Funding: Eli Lilly and Company.

Keywords: Asia; Diabetes Mellitus; Hypoglycemia; Insulin; Patient-reported outcomes; Type 2.

References

    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35:1364–1379. doi: 10.2337/dc12-0413.
    1. Wang W, McGreevey WP, Fu C, Zhan S, Luan R, Chen W, et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care. 2009;15:593–601.
    1. International Diabetes Federation. IDF Diabetes Atlas: Sixth Edition. International Diabetes Federation Brussels, Belgium. Available at . Accessed May 20, 2015.
    1. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747. doi: 10.1056/NEJMoa0905479.
    1. Shim YT, Lee J, Toh MP, Tang WE, Ko Y. Health-related quality of life and glycaemic control in patients with Type 2 diabetes mellitus in Singapore. Diabet Med. 2012;29:e241–e248. doi: 10.1111/j.1464-5491.2012.03689.x.
    1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. doi: 10.2337/dc08-9025.
    1. Japan Diabetes Society. Treatment Guide for Diabetes 2012–2013. . Accessed Apr 1, 2015.
    1. Chinese Diabetes Society China guideline for type 2. Diabetes. 2013;2014(6):447–498.
    1. Korean Diabetes Association. Korean Diabetes Research Foundation, and International Conference on Diabetes and Metabolism 2013. Diabetes Fact Sheet in Korea 2013. . Accessed Apr 10, 2015.
    1. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012;29:e13–e20. doi: 10.1111/j.1464-5491.2012.03586.x.
    1. Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ. 2011;37:111–123. doi: 10.1177/0145721710388426.
    1. Patrick AR, Fischer MA, Choudhry NK, Shrank WH, Seeger JD, Liu J, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2014;29:320–327. doi: 10.1007/s11606-013-2643-6.
    1. Polinski JM, Curtis BH, Seeger JD, Choudhry NK, Zagar A, Shrank WH. Rationale and design of the multinational observational study assessing insulin use: the MOSAIc study. BMC Endocr Disord. 2012;12:20. doi: 10.1186/1472-6823-12-20.
    1. Tan AM, Muthusamy L, Ng CC, Phoon KY, Ow JH, Tan NC. Initiation of insulin for type 2 diabetes mellitus patients: what are the issues? A qualitative study. Singap Med J. 2011;52:801–809.
    1. Wong S, Lee J, Ko Y, Chong MF, Lam CK, Tang WE. Perceptions of insulin therapy amongst Asian patients with diabetes in Singapore. Diabet Med. 2011;28:206–211. doi: 10.1111/j.1464-5491.2010.03195.x.
    1. Polinski JM, Smith BF, Curtis BH, Seeger JD, Choudhry NK, Connolly JG, et al. Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ. 2013;39:53–65. doi: 10.1177/0145721712467696.
    1. Ishii H, Terauchi Y, Jinnouchi H, Taketsuna M, Takeuchi M, Imaoka T. Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: the insulin-changing study intending to gain patients’ insights into insulin treatment with patient-reported health outcomes in actual clinical treatments (INSIGHTs) study. J Diabetes Investig. 2013;4:560–570. doi: 10.1111/jdi.12086.
    1. Polinski JM, Connolly JG, Curtis BH, Seeger JD, Gaskins K, Perez M, et al. Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review. Prim Care Diabetes. 2014;8:101–109. doi: 10.1016/j.pcd.2013.10.008.
    1. Polinski JM, Kim SC, Jiang D, Hassoun A, Shrank WH, Cos X, et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc) BMC Endocr Disord. 2015;15:46. doi: 10.1186/s12902-015-0044-z.
    1. Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28:626–631. doi: 10.2337/diacare.28.3.626.
    1. Fitzgerald JT, Funnell MM, Hess GE, Barr PA, Anderson RM, Hiss RG, et al. The reliability and validity of a brief diabetes knowledge test. Diabetes Care. 1998;21:706–710. doi: 10.2337/diacare.21.5.706.
    1. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–694. doi: 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>;2-I.
    1. Ji L, Su Q, et al. Glycemic control and self-monitoring of blood glucose in Chinese patients with type 2 diabetes on insulin: baseline results from the COMPASS study. Diabetes Res Clin Pract. 2016;112:82–87. doi: 10.1016/j.diabres.2015.08.005.
    1. Ji L, Zhang P, et al. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled by oral hypoglycemic agents in china-study design and baseline characteristics. Diabetes Technol Ther. 2015;17(10):735–744. doi: 10.1089/dia.2015.0054.
    1. Kanatsuka A, Kawai K, Hirao K, Yokoyama H, Kobayashi M. The initiation of insulin therapy in type 2 diabetic patients treated with oral anti-diabetic drugs: an observational study in multiple institutes across Japan (JDDM27) Diabetol Int. 2012;3:164–173. doi: 10.1007/s13340-012-0073-z.
    1. Kim SS, Kim IJ, Kim YK, Yoon KH, Son HY, Park SW, et al. Duration of diabetes and effectiveness of insulin in the management of insulin-naive Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MOdaliTy of Insulin treatment eValuation (MOTIV) registry results. Acta Diabetol. 2014;51:655–661. doi: 10.1007/s00592-014-0572-4.
    1. Yang W, Lu J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–1101. doi: 10.1056/NEJMoa0908292.
    1. Charvat H, Goto A, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig. 2015;6(5):533–542. doi: 10.1111/jdi.12333.
    1. Korean Diabetes Association. Korean Diabetes Fact Sheet 2015 Edition. . Accessed Apr 28, 2016.
    1. Tsai ST, Pathan F, Ji L, Yeung VT, Chadha M, Suastika K, et al. First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011;3:208–216. doi: 10.1111/j.1753-0407.2011.00137.x.
    1. Korean Diabetes Association. Korean Diabetes Association Guidelines 2013.
    1. National Development and Reform Commission of the People’s Republic of China. Notification Number [2012]4134: Maximum Retail Pricing of Drugs. . Accessed Apr 13, 2015.
    1. National Health and Family Planning Commission of the People’s Republic of China. National essential drug list (2012 edition). . Accessed Oct 2, 2015.
    1. Yang J, Li J. Premixed or basal insulin: the insulin initiation consideration in Chinese patients with type 2 diabetes mellitus. Chin J Endocrinol Metab. 2013;29(5):5b–5b1.
    1. Kohro T, Yamazaki T, Sato H, Harada K, Ohe K, Komuro I, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54:93–97. doi: 10.1536/ihj.54.93.
    1. Zagarins SE, Allen NA, Garb JL, Welch G. Improvement in glycemic control following a diabetes education intervention is associated with change in diabetes distress but not change in depressive symptoms. J Behav Med. 2012;35:299–304. doi: 10.1007/s10865-011-9359-z.
    1. Wardian J, Sun F. Factors associated with diabetes-related distress: implications for diabetes self-management. Soc Work Health Care. 2014;53:364–381. doi: 10.1080/00981389.2014.884038.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir